The Irish tax authority Revenue Commissioners has issued a Notice of Amended Assessment (NoA) to Perrigo stating the company owes €1.64bn in tax from 2013 intellectual property sales by Elan Pharma, which was later acquired by Perrigo.

The notice states that Elan’s sales of intellectual property, including multiple sclerosis drug Tysabri, to Biogen Idec were classified as trading income, when they should have been treated as chargeable gains. Therefore, the sales were only subject to a 12.5% tax rate, rather than the necessary 33%, and the outstanding amount should be taxed for the 2013 financial year.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Perrigo responded to the notice by filing a report to the US Securities and Exchange Commission (SEC); the company is listed on the New York Stock Exchange, but is headquartered in Dublin, Ireland.

In the SEC filing, the company stated it ‘strongly disagrees with this assessment and believes that the NoA is without merit and incorrect as a matter of law’ and ‘will timely file an appeal with the Irish Tax Appeals Commission’; the deadline for an appeal is 28 December 2018.

The company goes on to say: “Perrigo strongly disagrees with both the basis on which Elan Pharma has been assessed and the methodology used to calculate the amount set out in the NoA. Perrigo firmly believes that the NoA is without merit and that Irish Revenue’s position is incorrect as a matter of law.

“Perrigo also believes that, based on applicable case law, Irish Revenue’s published guidance on what constitutes a trade for Irish tax purposes, and related published precedents, Elan Pharma’s tax returns were filed correctly.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The €1.64bn amount does not include any interest or penalties associated with the tax assessment. This is believed this is the largest tax demand issued by the Revenue Commissioners in Ireland.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now